Update on the management of acute graft-versus-host disease

Current Opinion in Oncology

Volumn 18, Issue 2, 2006, Pages 120-125

  Bolaños Meade, Javier ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acute graft versus host disease; Pentostatin; Steroid refractory graft versus host disease

Indexed keywords

ALEMTUZUMAB; BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; BLINDNESS; GRAFT VERSUS LEUKEMIA EFFECT; HEADACHE; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; OUTPATIENT; PHOTOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; REVIEW; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

ACUTE DISEASE; ANTIBIOTIC PROPHYLAXIS; ANTIBODIES, MONOCLONAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ULTRAVIOLET THERAPY;

EID: 33646687483     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000208783.69076.7e     Document Type: Review

References (33)

1. Bolaños-Meade J, Vogelsang GB. Acute graft-versus-host disease. Clin Adv Hematol Oncol 2004; 2:672-682. Comprehensive review of aGVHD.
2. Bolaños-Meade J, Vogelsang GB. Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol 2005; 12:40-44. Comprehensive review on steroid-refractory aGVHD.
3. Fuchs EJ, Luznik L, Chen AR, et al. Post-transplantation cyclophosphamide (Cy) reduces graft rejection and graft-versus-host disease (GVHD) after non-myeloablative, partially HLA-mismatched (haploidentical) bone marrow transplantation (BMT) [abstract]. Blood 2004; 104(11 Suppl 1):Abstract 437. Interesting report discussing the use of high-dose cyclophosphamide for GVHD prophylaxis in haploidentical SCT.
4. + selection for GVHD prophylaxis in haploidentical SCT.
5. Kanda Y, Oshima K, Asano-Mori Y, et al. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79:1351-1357.
6. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34:621-625.
7. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11:495-505.
8. Loren AW, Luger SM, Stadtmauer EA, et al. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation. Bone Marrow Transplant 2005; 35:921-926.
9. Uberti JP, Ayash L, Braun T, et al. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes. Bone Marrow Transplant 2004; 34:425-431.
10. Fay JW, Wingard JR, Antin JH, et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation. Blood 1996; 87:3514-3519.
11. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-1441.
12. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11:389-398.
13. Yanada M, Emi N, Naoe T, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 2004; 34:331-337.
14. Bolaños-Meade J, Ioffe O, Hey JC, et al. Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung. Am J Hematol 2005; 79:132-135.
15. Beschorner WE, Saral R, Hutchins GM, et al. Lymphocytic bronchitis associated with graft-versus-host disease in recipients of bone-marrow transplants. N Engl J Med 1978; 299:1030-1036.
16. Gilman AL, Rackley C, Goldman F, et al. Cardiac manifestations of graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11 (2 suppl 1):47.
17. Goldberg J, Jacobsohn DA, Zahurak ML, Vogelsang GB. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:101-107. An interesting relationship between conditioning-induced diarrhea and risk of aGVHD.
18. Oh H, Loberiza FR Jr, Zhang MJ, et al. Comparison of graft-versus-host- disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood 2005; 105:1408-1416. The risk of aGVHD may depend on ethnicity, as reported in this study.
19. Wetzig T, Sticherling M, Simon JC, et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005; 35:515-519. Preliminary data on the use of long-wavelength ultraviolet A phototherapy as first-line therapy for GVHD.
20. Kanekiyo T, Hara J, Matsuda-Hashii Y, et al. Tacrolimus-related encephalopathy following allogeneic stem cell transplantation in children. Int J Hematol 2005; 81:264-268.
21. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11:551-557. This report explores in detail the risk of thrombotic microangiopathy after SCT in patients receiving sirolimus for GVHD prophylaxis.
22. Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, et al. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion 2003; 43:78-84.
23. Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-containing and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11:383-388. This report explores in detail the risk of mucositis after SCT in patients receiving different types of GVHD prophylaxis.
24. Kataoka I, Kami M, Takahashi S, et al. Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party. Bone Marrow Transplant 2004; 34:711-719.
25. Bolaños-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23:2661-2668. Interesting report on the use of pentostatin for patients with steroid-refractory aGVHD.
26. Mayer J, Krejci M, Doubek M, et al. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant 2005; 35:699-705. The use of cyclophosphamide for patients with steroid-refractory GVHD is discussed.
27. Carpenter PA, Lowder J, Johnston L, et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:465-471. Report of the efficacy of visilizumab to treat steroid-refractory aGVHD.
28. Passweg JR, Orchard K, Buergi A, et al. Autologous/syngeneic stem cell transplantation to treat refractory GvHD. Bone Marrow Transplant 2004; 34:995-998.
29. Patriarca F, Sperotto A, Damiani D, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004; 89:1352-1359.
30. Jacobsohn DA, Hallick J, Anders V, et al. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003; 74:119-124.
31. Shaughnessy PJ, Bachier C, Grimley M, et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:188-193. Another report on the use of denileukin diftitox for treatment of steroid-refractory aGVHD.
32. Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35:1003-1010.
33. Iyer RV, Hahn T, Roy HN, et al. Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:587-592. This study enriches the literature on the use of topical steroids for refractory gut aGVHD.